BC Week In Review | Sep 28, 2018
Company News

Opiant gets BARDA grant for intranasal opioid antagonist

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...
BC Extra | Sep 20, 2018
Company News

Opiant gets BARDA grant for intranasal opioid antagonist

HHS partnered with Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) to accelerate development of the company's OPNT003, an intranasal formulation of opioid receptor antagonist nalmefene. Under a one-year contract with HHS's Biomedical Advanced Research and Development Authority, Opiant...
BC Week In Review | Dec 1, 2017
Company News

Acorda cashes out on Selincro royalties

H. Lundbeck A/S (CSE:LUN) will pay Acorda Therapeutics Inc. (NASDAQ:ACOR) $13 million to eliminate milestone and royalty payments tied to ex-U.S. sales of Selincro nalmefene. Lundbeck licensed the alcohol dependence drug from BioTie Therapies Corp.,...
BC Week In Review | Nov 30, 2017
Clinical News

Otsuka submits Japanese NDA for nalmefene to treat alcohol dependence

In October, Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) submitted a Japanese NDA for nalmefene to treat alcohol dependence. Otsuka and H. Lundbeck A/S (CSE:LUN) co-developed nalmefene for alcohol dependency in Japan. It is marketed as...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BC Week In Review | Dec 8, 2014
Clinical News

Selincro nalmefene regulatory update

The U.K.’s NICE issued final guidance recommending the use of Selincro nalmefene from H. Lundbeck to reduce alcohol consumption in adults with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms...
BC Extra | Dec 5, 2014
Company News

IQWiG: Selincro's benefit to heavy drinkers unproven

The German Institute for Quality and Efficiency in Health Care (IQWiG) said H. Lundbeck A/S (CSE:LUN) did not show Selincro nalmefene offered benefit over comparator naltrexone to reduce alcohol consumption by adults with dependence who...
BC Extra | Nov 26, 2014
Company News

NICE recommends Selincro for alcohol dependence

The U.K.'s NICE issued final guidance recommending the use of Selincro nalmefene from H. Lundbeck A/S (CSE:LUN) to reduce alcohol consumption by adults with alcohol dependence who have a high drinking risk level without physical...
BC Week In Review | Oct 13, 2014
Clinical News

Selincro nalmefene regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Selincro nalmefene to help reduce alcohol consumption in adults with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms and who...
BC Week In Review | Sep 29, 2014
Company News

Biotie, Lundbeck sales and marketing update

Biotie said Lundbeck launched Selincro nalmefene in France to reduce alcohol consumption in adults with alcohol dependence. The launch triggered a milestone payment of EUR2 million ($2.6 million) to Biotie, which is the last milestone...
Items per page:
1 - 10 of 87